Andrew E. Ekpenyong, PhD

Nanoparticle-mediated radiation therapy (NPRT) is an emerging clinical research frontier which seeks to improve radiotherapy outcomes through local tumor dose enhancement and radiosensitization. We recently showed improved NPRT outcomes for 2D glioblastoma (G...

Glioblastoma (GBM) remains a lethal brain cancer with a devastating median survival of about 15 months with the current standard of treatment involving surgery, radiation therapy, and chemotherapy utilizing temozolomide (TMZ). Radioimmunotherapy (RIT), combin...

Glioblastoma is highly aggressive and the most prevalent brain tumor in adults. The median survival of patients is 15 months, despite the current standard of care comprising surgery, radiotherapy, and chemotherapy. Hence, new therapeutic approaches are urgent...